0030 GMT - ResMed keeps its bull at Macquarie on what the investment banks' analysts see at positive medium-term demand catalysts and the likelihood of sustained near-term margin expansion. Maintaining an outperform rating on the stock, the Macquarie analysts write in a note that the breathing-tech manufacturer's 4Q margin was stronger than they had anticipated. They attribute the beat to operational efficiencies, including in procurement, manufacturing, and logistics. With capital returns accelerating and awareness of sleep apnea rising, Macquarie lifts its target price on the stock by 5.9% to A$48.60. Shares are up 4.6% at A$44.88. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
August 04, 2025 20:30 ET (00:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.